These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11814832)

  • 1. Structural development of biological response modifiers based on thalidomide.
    Hashimoto Y
    Bioorg Med Chem; 2002 Mar; 10(3):461-79. PubMed ID: 11814832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel biological response modifiers derived from thalidomide.
    Hashimoto Y
    Curr Med Chem; 1998 Jun; 5(3):163-78. PubMed ID: 9562600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide as a multi-template for development of biologically active compounds.
    Hashimoto Y
    Arch Pharm (Weinheim); 2008 Sep; 341(9):536-47. PubMed ID: 18389516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural development of biological response modifiers based on retinoids and thalidomide.
    Hashimoto Y
    Mini Rev Med Chem; 2002 Dec; 2(6):543-51. PubMed ID: 12370039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents.
    El-Zahabi MA; Sakr H; El-Adl K; Zayed M; Abdelraheem AS; Eissa SI; Elkady H; Eissa IH
    Bioorg Chem; 2020 Nov; 104():104218. PubMed ID: 32932121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel biological response modifiers: phthalimides with TNF-alpha production regulating activity].
    Miyachi H; Azuma A; Hashimoto Y
    Yakugaku Zasshi; 1997 Feb; 117(2):91-107. PubMed ID: 9084226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
    Yamamoto T; Shibata N; Sukeguchi D; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H; Tanaka M; Obata T; Sasaki T
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3973-6. PubMed ID: 19297157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological properties of thalidomide and its analogues.
    De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural development of synthetic retinoids and thalidomide-related molecules.
    Hashimoto Y
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S16-23. PubMed ID: 12819930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor.
    Hu S; Yuan L; Yan H; Li Z
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4075-4081. PubMed ID: 28757066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13.
    Grzywa R; Sokol AM; Sieńczyk M; Radziszewicz M; Kościołek B; Carty MP; Oleksyszyn J
    Bioorg Med Chem; 2010 Apr; 18(8):2930-6. PubMed ID: 20347318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine.
    Luzzio FA; Mayorov AV; Ng SS; Kruger EA; Figg WD
    J Med Chem; 2003 Aug; 46(18):3793-9. PubMed ID: 12930142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer.
    Capitosti SM; Hansen TP; Brown ML
    Bioorg Med Chem; 2004 Jan; 12(2):327-36. PubMed ID: 14723953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity.
    Nakamura T; Noguchi T; Kobayashi H; Miyachi H; Hashimoto Y
    Chem Pharm Bull (Tokyo); 2006 Dec; 54(12):1709-14. PubMed ID: 17139107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulators of tumor necrosis factor alpha production bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore.
    Tsuji M; Koiso Y; Takahashi H; Hashimoto Y; Endo Y
    Biol Pharm Bull; 2000 Apr; 23(4):513-6. PubMed ID: 10784439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives.
    da Costa PM; da Costa MP; Carvalho AA; Cavalcanti SM; de Oliveira Cardoso MV; de Oliveira Filho GB; de Araújo Viana D; Fechine-Jamacaru FV; Leite AC; de Moraes MO; Pessoa C; Ferreira PM
    Chem Biol Interact; 2015 Sep; 239():174-83. PubMed ID: 26134001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Thalidomide-Resembling Dicarboximides Target ABC50 Protein and Show Antileukemic and Immunomodulatory Activities.
    Cieślak M; Kaźmierczak-Barańska J; Królewska-Golińska K; Napiórkowska M; Stukan I; Wojda U; Nawrot B
    Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31487824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of thalidomide and its IMiD derivatives as anticancer agents.
    Bartlett JB; Dredge K; Dalgleish AG
    Nat Rev Cancer; 2004 Apr; 4(4):314-22. PubMed ID: 15057291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.